Non-Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Atezolizumab plus bevacizumab and chemotherapy prolongs PFS in non-small cell lung cancer - Healio



OncLive
 
Atezolizumab plus bevacizumab and chemotherapy prolongs PFS in non-small cell lung cancer 
Healio
The addition of atezolizumab to first-line treatment with bevacizumab and chemotherapy extended PFS by 38% among individuals with advanced nonsquamous non-small cell lung cancer, according to the agent's manufacturer. Atezolizumab (Tecentriq, Genentech ...
Frontline Atezolizumab Regimen Improves PFS in NSCLC OncLive
New first line combination therapy shows promising results in patients with advanced NSCLC News-Medical.net
Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival Labiotech.eu (blog)

all 8 news articles » 


Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received ... - Dove Medical Press



Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received ... 
Dove Medical Press
Background: Non-small cell lung cancer (NSCLC) is the predominant cause of death in patients with COPD, and the severity of COPD in NSCLC patients is classified mainly as mild to moderate. Most advanced NSCLC patients with mild to moderate COPD are ...

 


Americas Tops the Global Lung Cancer Liquid Biopsy Market | Technavio - Business Wire (press release)



Business Wire (press release)
 
Americas Tops the Global Lung Cancer Liquid Biopsy Market | Technavio 
Business Wire (press release)
Rising incidence of lung cancer is one of the major factors driving the global lung cancer liquid biopsy market. Lung cancer is regarded as one of the highest causes of cancer deaths across the globe. The two types of lung cancers that grow and spread ...

and more » 


Optimal Sequencing and Patient Selection Investigated in NSCLC - OncLive



OncLive
 
Optimal Sequencing and Patient Selection Investigated in NSCLC 
OncLive
OncLive: Can you discuss molecular profiling for patients with adenocarcinoma of the lung? Mott: Adenocarcinoma of the lung has come a long way in the last decade in terms of new treatment options based on molecular targets. It is now standard of care ...

and more » 


Expert Discusses Developments in ALK/ROS1-Positive NSCLC - OncLive



OncLive
 
Expert Discusses Developments in ALK/ROS1-Positive NSCLC 
OncLive
OncLive: Please provide an overview of your presentation. Lam: I discussed the latest developments for patients with ALK- and ROS1-positive NSCLC. We are seeing that treatment development is much better with the ALK-targeted therapies compared with ...

 


ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology ... - Markets Insider



ARMO BioSciences Presents Data from its Phase 1b Trial in Non-Small Cell Lung Cancer at ESMO Immuno Oncology ... 
Markets Insider
REDWOOD CITY, Calif., Dec. 9, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today released additional clinical trial results on its lead investigational immuno-oncology drug AM0010 (pegilodecakin) in non-small cell ...

and more » 


Emerging Therapies for Nonsquamous NSCLC - OncLive



OncLive
 
Emerging Therapies for Nonsquamous NSCLC 
OncLive
There are also other agents in the immunity cycles that are currently under investigation in combination with PD-1 inhibitors. My personal take is that we still need to learn a lot about PD-L1 inhibition before moving forward, because in this kind of ...

 


Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer - Pharmacy Today, American Pharmacists Association, pharmacist.com



Targeted Oncology
 
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer 
Pharmacy Today, American Pharmacists Association, pharmacist.com
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. Share This Page. November 22, 2017. The purpose of the FLAURA study was to compare epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in treating advanced ...
New Results Uphold Frontline Osimertinib Benefit Against CNS Mets in NSCLC Targeted Oncology

all 2 news articles » 


Current Treatment Strategies in Nonsquamous Non-Small Cell Lung Cancer - Targeted Oncology



Current Treatment Strategies in Nonsquamous Non-Small Cell Lung Cancer 
Targeted Oncology
NONSQUAMOUS NON?SMALL CELL LUNG CANCER (NSCLC) is a heterogeneous disease with multiple treatment options dependent upon staging, presence of metastasis, and patient factors?including presence of comorbidities?among other considerations. As such ...

 


Combo Biologics Slow NSCLC Disease Progression, Death (Genentech - MedPage Today



PharmaTimes
 
Combo Biologics Slow NSCLC Disease Progression, Death (Genentech 
MedPage Today
Advanced non-small cell lung cancer (NSCLC) patients treated with two monoclonal antibodies -- Tecentriq (atezolizumab) and Avastin (bevacizumab) -- plus chemotherapy showed significantly reduced risk of disease progression and death in phase III trial ...
Roche lung cancer combo doubles PFS rates PharmaTimes
Adding Tecentriq to Lung Cancer Treatment Boosts PFS 38% in Trial Managed Care magazine
Data backs up Roche's Tecentriq/Avastin combo in lung cancer PMLiVE
MedCity News  -Zacks.com  -pharmaphorum 
all 47 news articles »